• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1277484 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type7 {: e; T# R0 H  M; m' A
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 5 H. u# ]2 G' P* g- U( r5 U! ]
+ Author Affiliations
" V4 V9 A- f. f' @9 m6 w  X1 ^% {% }7 n: o% F4 c
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 z9 a$ j$ o2 I- m' l2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 K7 q& N2 K" J6 m3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
1 ]3 O6 D( s' M2 @4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
; c4 }) k) m- H* b3 q( y5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan , {  d) P: Z: E* @* o- {% I; X2 o6 R* E
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
0 Z4 D) ]$ A3 {, j+ u: q7Kinki University School of Medicine, Osaka 589-8511, Japan 7 i6 t  v0 ^" V/ A
8Izumi Municipal Hospital, Osaka 594-0071, Japan & L$ `7 L8 Y- f- C& W0 ^* P
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
4 C8 H/ j* ^; T8 s- }  ]Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp , Q) ^4 l, Q; P$ V4 m. J
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
* S7 P8 p; W0 U' h0 S5 f+ |
! P3 k6 }5 J, g4 M$ H: q* i
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type : P. z1 I4 J2 ]9 j. j& ^) o8 e
3 N6 v* ^* n' q8 U7 x
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
# i+ a( r% A5 a# i  u
. i  d; L. X# j8 ?: L% t# R% Y# dAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  5 [9 B3 d: r! {1 X

+ B$ v9 g* `: `& F4 U1 @Published online on: Thursday, December 1, 2011 ) |; g5 N, V9 ^( C" j2 n
* E: ]; P' ]% ^) C& t; Y2 [$ ~
Doi: 10.3892/ol.2011.507 # Y7 N2 U4 K* j: I! g9 p

, L3 y: n4 ?' ]6 B; wPages: 405-410 * S" g  f% I. i" {( ~! j2 }' U

1 _- u5 Q) Q# {8 I$ Q+ ZAbstract:
: X6 T) G. I. t. CS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
) Y+ J8 N! A3 }
' F2 `+ F$ d/ M. _; b8 }7 X' B! ?
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
% S4 ~  [$ a. A0 \& jF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 3 _+ g0 p' Z  e% I1 T) U
+ Author Affiliations
* H' `8 O& j! [# x; t" D* X1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 0 e* M1 n' W, r. G# z9 G2 F
2Department of Thoracic Surgery, Kyoto University, Kyoto 2 S/ _  ?: H* g0 ?$ Q" u! s
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
. p+ K2 ?% T3 b" x# ^&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 2 v4 U1 q0 W% t0 V3 i' g+ E9 {
Received September 3, 2010.
! A/ i" b$ z) M1 qRevision received November 11, 2010.
' j  s* ?3 m* OAccepted November 17, 2010. 9 ~' m9 M3 E$ e* I/ H: D+ N9 U
Abstract9 P, a& M# d% m! {) j
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
% {6 p$ K: ?, S- A! l8 x, ~, H2 K0 @/ ^Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
4 m  q" j* d' [9 qResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
) W/ O7 }; L+ t, u- UConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 7 A9 }1 [  |: N4 h
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。$ m: F" X& P# j7 T/ R4 H; G' H9 K
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
3 `! b" P2 n& _# B- V! l1 K- }
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy6 l$ M  q, s0 H8 B  U  @( s
http://clinicaltrials.gov/ct2/show/NCT015235870 U$ s" y0 v' e& z6 f
2 B- k! t& j  X& u: V
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC2 Z5 n7 E# U: m& E# v5 j
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
$ y0 `) e8 K7 f6 A; L, r! u5 j3 z* I- C8 M2 S5 k
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
" c+ @) s4 f! F( `" M5 |至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
+ P5 [5 A, D9 V7 M, A4 L( R从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
# f, B3 d9 q; E9 P1 t8 f! r+ c  l至今为止,未出 ...

5 o7 T3 L* I9 p3 D没有副作用是第一追求,效果显著是第二追求。1 |3 u) i: A" }8 u
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表